Skip to main content
. 2022 Nov 22;40(2):585–600. doi: 10.1007/s12325-022-02369-x

Fig. 1.

Fig. 1

MSQv2 (A) role function restrictive, B role function prevention, and C emotional function domains over the double-blind treatment and open-label extension phases of study 305 for patients starting on rimegepant vs. placebo